The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer
Authors:
- Yuki HamadaYHYuki Hamada
- Kiyonori TanoueKTKiyonori Tanoue
- Takaaki ArigamiTATakaaki Arigami
- Munekazu YamakuchiMYMunekazu Yamakuchi
- Masashi OkawaMOMasashi Okawa
- Daisuke MatsushitaDMDaisuke Matsushita
- Kazunori TakenouchiKTKazunori Takenouchi
- Shingo YamadaSYShingo Yamada
- Drew N. MaywarDMDrew N. Maywar
- Chieri NakayamaCNChieri Nakayama
- Yoko OyamaYOYoko Oyama
- Sadayuki HigashiSHSadayuki Higashi
Open Access
Abstract
Background/Objectives: The response rate to immune checkpoint inhibitor (ICI) therapy is limited. Further, there is a need to discover biomarkers to predict therapeutic efficacy. The vascular endothelial growth factor (VEGF) is strongly associated with intra-tumoral immunity; however, its utility as a marker remains unknown. Therefore, our objectives were to examine the isoforms of VEGF and determine whether VEGF levels predict ICI efficacy. Methods: Levels of VEGF isoforms VEGF-A121 and VEGF-A165 were measured in stored serum samples obtained from 30 patients with advanced or recurrent gastric cancer who received nivolumab monotherapy at Kagoshima University Hospital, and the association with prognosis and treatment efficacy was retrospectively analyzed. Results: The serum levels of the total VEGF, VEGF-A121, and VEGF-A165 were not significantly associated with prognosis. However, the ratio of VEGF-A121/VEGF-A165 (VEGF-A121/165) exhibited a statistically significant (p = 0.0088) difference in progression-free survival (PFS) with the low-ratio group having a 67-day prolonged median PFS time. Under univariable analysis, only VEGF-A121/165 values exhibited reduced progression-free survival with statistical significance. When comparing treatment responses in the low (n = 15) and high (n = 15) serum VEGF-A-121/165 groups, RECIST evaluation was 3 to 0 for complete response (CR), 2 to 0 for partial response (PR), 3 to 2 for stable disease (SD), and 3 to 10 for progressive disease (PD). Patients with clinically unsettled PR or SD were classified as non-CR/non-PD (4 vs. 3), with a disease control rate of 80% vs. 33%. Conclusions: The serum VEGF-A121/165 ratio may represent a new, easily measured biomarker for predicting the therapeutic response to ICIs.Keywords
Funding Information
- JSPS KAKENHI (19K09200, 21K08783, 22K16538)
This publication has 46 references indexed in Scilit:
- Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancerCancer Immunology, Immunotherapy, 2020
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyEuropean Journal of Cancer, 2020
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2018
- Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung AdenocarcinomaJournal of Thoracic Oncology, 2018
- Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial CarcinomaJournal of Urology, 2018
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic reviewCancer Letters, 2018
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Angiogenesis, 2017
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2International Journal of Cancer, 2011